# Immunovant Announces Pricing of $550 Million Common Stock Financing
Canonical URL: https://biopharmsignal.com/news/IMVT/immunovant-announces-pricing-of-550-million-common-stock-financing
Ticker: IMVT
Company: Immunovant
Source: Immunovant
Published: 2025-12-11 06:29 EST
Original Source URL: https://www.immunovant.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-23 20:05 EST — [Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45) — Source: Immunovant
- 2026-05-20 11:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026) — Source: Immunovant
- 2026-05-11 20:05 EST — [Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Immunovant
- 2026-04-02 09:00 EST — [Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)](https://biopharmsignal.com/news/IMVT/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted) — Source: Immunovant
- 2026-02-06 12:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-third-quarter-ended-december-31-2025) — Source: Immunovant
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)